Norbert Bischofberger, PhD, is a senior advisor at Norwest, providing counsel to Norwest’s healthcare portfolio companies in the biotech space.

He is the Chief Executive Officer of NextQuest LLC. He joined Kronos Bio in May 2018, where he served as President and CEO until December 2024.

Before his tenure at Kronos Bio, Norbert was the Executive Vice President, Research and Development and Chief Scientific Officer at Gilead Sciences. He began his career at Gilead in 1990 as Director of Chemistry after working as a Senior Scientist in Genentech’s DNA Synthesis Group from 1986 to 1990.

During his 28-year tenure at Gilead, Norbert presided over the development and approval of more than 25 medicines for a range of serious conditions which led the transformation of the treatment of diseases such as HIV, HCV and lymphoma. He was a key member of the management team that expanded Gilead from a small company with fewer than 50 employees and no revenue to a major corporation with 10,000 employees and $25 billion in revenue.

Norbert received a Ph.D. in organic chemistry from Zurich’s Eidgenössische Technische Hochschule and performed postdoctoral research in steroid chemistry at Syntex. He furthered his research in organic chemistry and applied enzymology in Professor George Whiteside’s lab at Harvard University. Norbert received an honorary doctorate in Natural Sciences (2016) from The University of Innsbruck and an honorary doctorate in Letters in Medicine (2017) from Baylor College of Medicine. Norbert was elected a Fellow of The American Association for Advancement of Science (2018).

Norbert serves on the Board of Directors of Kronos Bio and Vir Biotechnology.